|
| Press Releases |
|
 |
|
| Wednesday, December 20, 2023 |
|
|
Ocumension Therapeutics: The Approval Received For Marketing OT-703 In Hong Kong, A New Option For Patients With Diabetic Macular Edema |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, is pleased to announce that, OT-703 (ILUVIEN(R), fluocinolone intravitreal implant), an injectable more info >> |
|
| Thursday, August 24, 2023 |
|
|
Ocumension Therapeutics Announces 2023 Interim Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, announced its interim results for the six months ended 30 June 2023 ("the Period") today. more info >> |
|
| Thursday, March 30, 2023 |
|
|
Ocumension Therapeutics Announces 2022 Annual Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, announced its annual results for the year ended 31 December 2022 today. more info >> |
|
| Monday, March 13, 2023 |
|
|
Ocumension Therapeutics Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, is pleased to announce that the Company's ordinary shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), are included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective on March 13, 2023. more info >> |
|
| Tuesday, February 14, 2023 |
|
|
Ocumension Therapeutics Issues Positive Profit Alert for 2022 Annual Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, is pleased to announce that it is anticipated that the Company will record a significant increase in its revenue and gross profit for the year ended 31 December 2022 (the "Year 2022"). more info >> |
|
| Friday, February 3, 2023 |
|
|
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202 |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that the phase I clinical trial of OT-202 (tyrosine kinase inhibitor), a class I new drug developed by the Company for the treatment of dry eye, has been completed successfully. more info >> |
|
| Wednesday, February 1, 2023 |
|
|
Ocumension Therapeutics Announces Its Patient Enrollment Completed In The Phase III Clinical Trail Of OT-101 In China |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that OT-101 (0.01% atropine sulfate eye drop) more info >> |
|
| Monday, January 30, 2023 |
|
|
Ocumension Therapeutics Appoints Mr. Tim RUAN and Mr. WANG Chong as Chief Financial Officer and Head of Investor Relations respectively |
| Ocumension Therapeutics (1477.HK) is pleased to announce that Mr. Tim RUAN and Mr. WANG Chong have been appointed as Chief Financial Officer and Head of Investor Relations respectively of the Group. more info >> |
|
| Saturday, March 20, 2021 |
|
|
Ocumension Therapeutics (1477.HK) Announces 2020 Annual Results |
| The Chinese ophthalmology platform company, Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, the "Group" ), (stock code: 1477.HK), announced its annual results for the year ended 31 December 2020 today. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
JCB and Agoda Enter Long-Term Partnership to Enhance Travel and Payment Experience Across Asia 
Nov 6, 2025 12:00 JST
|
|
|
WOA Crypto Announces Sustainable Cloud Mining Advancements, Supporting the Growth of Accessible Digital Assets
Nov 6, 2025 08:22 HKT/SGT
|
|
|
The Michelin Guide Expands Its Global Footprint with the Arrival in Aotearoa New Zealand
Nov 6, 2025 07:00 HKT/SGT
|
|
|
Wintermar Offshore (WINS:JK) Reports 9M2025 Results
Nov 5, 2025 22:38 HKT/SGT
|
|
|
The Hong Kong International Optical Fair opens today
Nov 5, 2025 19:14 HKT/SGT
|
|
|
SAP Empowers Developers to Drive the Business AI Revolution
Nov 5, 2025 16:27 HKT/SGT
|
|
|
The All-American Koi Show 2026 - Experience the World's Top Koi Exhibition in Las Vegas, NV
Nov 5, 2025 01:30 HKT/SGT
|
|
|
NEC and Siemens collaborate to accelerate smart factory innovation
Nov 4, 2025 0:57 JST
|
|
|
Exhibiting at the Space Tech Expo Europe 2025 in Bremen, Germany
Nov 4, 2025 0:49 JST
|
|
|
Honda Announces Electric Motorcycle Business Brand Promise and Four Core Values
Nov 4, 2025 0:35 JST
|
|
|
Honda Unveils Its First Electric Motorcycle, the Honda WN7, at EICMA 2025
Nov 4, 2025 0:20 JST
|
|
|
Honda Unveils V3R 900 E-Compressor Prototype Equipped with V3 Engine with Electronically-controlled Compressor at EICMA 2025
Nov 4, 2025 0:00 JST
|
|
|
New GA-ASI Gambit 6 UCAV Adds Air-To-Ground Operations for International CCA
Nov 4, 2025 23:00 HKT/SGT
|
|
|
Honda Presents World Premiere of CB1000GT Sport Tourer at EICMA 2025
Nov 4, 2025 23:55 JST
|
|
|
New CB1000GT, global debut of Honda WN7 electric motorcycle, expansion of Honda E-Clutch line-up and V3R 900 E-Compressor Prototype lead Honda's EICMA 2025 line-up
Nov 4, 2025 23:40 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
